Healthcare products company West Pharmaceutical Services (NYSE: WST) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 21% year on year to $844.9 million. Guidance for next quarter’s revenue was optimistic at $840 million at the midpoint, 2.2% above analysts’ estimates. Its non-GAAP profit of $2.13 per share was 27.1% above analysts’ consensus estimates.
Is now the time to buy WST? Find out in our full research report (it’s free for active Edge members).
West Pharmaceutical Services (WST) Q1 CY2026 Highlights:
- Revenue: $844.9 million vs analyst estimates of $779.1 million (21% year-on-year growth, 8.4% beat)
- Adjusted EPS: $2.13 vs analyst estimates of $1.68 (27.1% beat)
- Adjusted EBITDA: $226.2 million vs analyst estimates of $190 million (26.8% margin, 19.1% beat)
- The company lifted its revenue guidance for the full year to $3.32 billion at the midpoint from $3.25 billion, a 2.4% increase
- Management raised its full-year Adjusted EPS guidance to $8.58 at the midpoint, a 6.9% increase
- Operating Margin: 21%, up from 15.3% in the same quarter last year
- Market Capitalization: $22.32 billion
StockStory’s Take
West Pharmaceutical Services delivered a first quarter that exceeded Wall Street's expectations, driven by robust demand for its high-value product (HVP) components and operational improvements in its manufacturing facilities. Management credited the strong results to accelerated growth in both GLP-1 and non-GLP-1 HVP components, with CEO Eric Green pointing to the “tremendous execution of our operating unit strategy” and increased output, particularly in Europe. The company also saw notable momentum in its biologics business, as well as successful capacity ramp-ups that helped meet heightened demand.
Looking forward, West Pharmaceutical Services’ updated guidance reflects optimism around sustained growth in HVP components, further penetration of the biologics and biosimilars markets, and continued operational enhancements. Management believes that ongoing regulatory drivers—such as Annex 1 upgrades and global standardization initiatives—will provide durable tailwinds. CFO Robert McMahon emphasized that “margin expansion will continue,” supported by favorable product mix and efficiency gains, although he cautioned that the macro environment remains dynamic and the company will maintain prudent forecasting.
Key Insights from Management’s Remarks
Management attributed the quarter's outperformance to rapid HVP component adoption, enhanced operational capacity, and a mix shift toward higher-margin products, while also highlighting execution on key regulatory and regional growth initiatives.
-
HVP component acceleration: The core proprietary segment, especially HVP components, drove significant organic growth, fueled by strong uptake in GLP-1 therapies and non-GLP-1 applications such as biologics and biosimilars. Management noted this was supported by new product launches and high customer win rates in the biologics market.
-
Operational improvements: Enhanced onboarding and redeployment of employees, along with optimization of the global manufacturing network, allowed West Pharmaceutical Services to increase capacity and output, particularly in Europe. CEO Eric Green described the transfer of best practices across sites as a “significant benefit,” enabling the company to better meet rising customer demand.
-
Annex 1 regulatory tailwinds: The ongoing conversion of standard products to HVP components, driven by Annex 1 regulatory changes, contributed to both revenue and margin expansion. Management expects this regulatory-driven mix shift to be a multi-year positive for the business, with global adoption extending beyond Europe into the U.S. and Asia.
-
Biologics and biosimilars momentum: The biologics business delivered 26% organic growth, with the NovaPure platform highlighted for its quality attributes and success in new drug launches. The easing of regulations and the growth in biosimilar launches further expanded the addressable market.
-
West Vantage segment update: The newly branded West Vantage segment (formerly contract manufacturing) saw growth through drug handling services and the ramp-up of its new Dublin facility. Management expects this shift to higher-margin, less capital-intensive services to strengthen the segment’s profit profile over time.
Drivers of Future Performance
Looking ahead, West Pharmaceutical Services’ outlook is shaped by sustained demand for HVP components, regulatory-driven upgrades, and ongoing efficiency initiatives.
-
Sustained HVP growth: Management expects both GLP-1 and non-GLP-1 HVP components to drive low double-digit organic growth, supported by continued adoption in biologics and regulatory changes like Annex 1. This mix shift toward premium products is expected to underpin revenue and margin expansion throughout the year.
-
Operational efficiency and capacity scaling: The company is leveraging operational improvements to boost capacity and meet rising demand, with best practices from European plants being applied globally. These initiatives are anticipated to deliver further margin gains and enable faster customer onboarding and site qualification, which typically takes 6–12 months per transfer.
-
Macroeconomic and supply chain risks: Management highlighted ongoing vigilance in the face of commodity price pressures and potential supply chain disruptions. While mitigation strategies such as hedging and pricing adjustments are in place, the company remains cautious and will continue to monitor the impact of global events, including geopolitical uncertainties.
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will be watching (1) the pace of HVP conversion and Annex 1-driven upgrades across global markets, (2) the execution of operational improvements and capacity expansions at manufacturing sites, and (3) the progression of the West Vantage segment’s shift toward higher-margin drug handling services. Additionally, developments in GLP-1 adoption and biosimilar launches could further shape the company’s growth trajectory.
West Pharmaceutical Services currently trades at $312.13, up from $274.41 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).
Stocks That Trumped Tariffs
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
